The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...

According to a new report from Intel Market Research, the global Dual-Antibody ADC market was valued at USD 477 million in 2024 and is projected to reach USD 691 million by 2032, exhibiting a steady CAGR of 6.2% during the forecast period (2025–2032). This growth is driven by increasing cancer prevalence and demand for precision medicine, superior tumor targeting capabilities of...